Clinical Trial Update: Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating first-line durvalumab and tremelimumab in combination with lenvatinib for unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• LENVIMA (lenvatinib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING